Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum FSD Pharma Inc C.HUGE

Alternate Symbol(s):  HUGE

FSD Pharma Inc. is a Canada-based biotechnology company. The Company operates through two segments: Biotechnology and Strategic Investments. Its Biotechnology segment is focused on furthering the research and development of the Company’s two primary drug candidates consisting of Lucid-MS and Lucid-PSYCH, as well as the development of UNBUZZD. The Company’s Strategic Investments segment is... see more

CSE:HUGE - Post Discussion

FSD Pharma Inc > New podcast with Dr Kotra talking
View:
Post by JensLens on Jun 14, 2022 11:21am

New podcast with Dr Kotra talking

Your Complex Brain: Psychedelics and the Mental Health Revolution on Apple Podcasts

More than 50 years after emerging as a potential treatment for anxiety and depression, addiction, post-traumatic stress disorder and other chronic illnesses, psychedelics appear to be making a comeback. But where does the research stand currently on psychedelics and what do we really know about how these compounds may affect the brain?


With the number of people living with mental health conditions on the rise and the re-emergence of psychedelics as a possible therapy, this topic is very timely. Some may call it a “perfect storm” – one the medical and scientific communities will need to carefully navigate, in order to tap the potential of psychedelics, safely and cautiously.


Featuring:

Dr. Susan Abbey is Psychiatrist-in-Chief at the University Health Network (UHN), and a Clinician Investigator with the Toronto General Hospital Research Institute.  She is also a Professor in the Department of Psychiatry at The University of Toronto and the inaugural Director of the Nikean Psychedelic Psychotherapy Research Centre at UHN.


Dr. Lakshmi Kotra is a Medicinal Chemist and Senior Scientist with Krembil Brain Institute and a Professor of Medicinal Chemistry at The University of Toronto. He is also an academic entrepreneur with three decades of expertise in drug discovery, development, and pharmaceuticals, and the co-founder and CEO of Lucid Psycheceuticals.


Additional Resources:

Nikean Psychedelic Psychotherapy Research Centre at UHN

First-of-its-kind research centre will bring psychedelic psychotherapy to UHN

The Revival of Psychedelic Research – ORT Times article

Lucid Psycheceuticals

Comment by Renofund on Jun 14, 2022 8:10pm
why do you keep changing your screen name, Rosie?  Honest question
Comment by Mil_Man54 on Jun 15, 2022 6:39am
I'm guessing it's for legal reasons and he's in enough trouble with the OSC.....
Comment by Mil_Man54 on Jun 15, 2022 3:46pm
That must have been some podcast Rosenberg....sure did wonders for the SP.
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities